Perfluorododecanoic acid (PFDoA)

Some of the chemicals your body takes in today will still be measurable years from now. Perfluorododecanoic acid is one of them, a synthetic compound so stable that your body has almost no way to break it down or clear it quickly.

Checking your level answers one practical question: how much of this persistent chemical have you accumulated from your surroundings? This test looks for it in urine, and there is an important caveat about that choice worth understanding before you read the rest.

A Forever Chemical, Not Something Your Body Makes

PFDoA (perfluorododecanoic acid) belongs to a family of thousands of synthetic chemicals known as PFAS (per- and polyfluoroalkyl substances), prized by industry because they resist stains, water, and heat. It is a long-chain member of that family, which matters for how it behaves in the body.

Your body does not produce this chemical anywhere. A measurable level reflects outside exposure that has been absorbed and retained, not a gland or organ working too hard or too little. In that sense it is an exposure marker: higher means more has come in and stuck around, lower means less.

Because these compounds degrade poorly, they persist in the environment and accumulate in people after absorption. That persistence is exactly why a single exposure can echo in your body for years.

Why Urine Is a Tricky Place to Measure It

This is the single most important thing to grasp about this test. For long-chain PFAS like PFDoA, the chemical concentrates heavily in blood and appears only faintly in urine. In national US testing, long-chain PFAS were essentially undetectable in urine: most people had no detectable urinary PFAS of any kind, even though blood testing suggested nearly everyone carried them.

Researchers who study this directly conclude that for long-chain PFAS, blood or serum is the more appropriate sample for measuring exposure, regardless of whether the exposure is everyday or occupational. Urine tends to undercapture the true body burden for this specific chemical.

There is a payoff, though. Paired studies show that urine and blood levels of many of these chemicals move together, so a detectable urine result can still signal internal dose. And the ratio between urine and blood carries useful information about how a given chemical is stored versus excreted. Just treat a low or undetectable urine value with caution: for PFDoA it may reflect the limits of the urine sample as much as low exposure.

Gestational Diabetes in Pregnancy

The clearest disease signal for this chemical comes from pregnancy. In a study of pregnant women in Shanghai, comparing 165 who developed gestational diabetes with 330 who did not, those with the highest early-pregnancy PFDoA levels had roughly 13 times the odds of gestational diabetes compared with women who had the lowest levels (adjusted odds ratio 13.00, 95% CI 4.74 to 24.59).

That confidence range is wide, so the exact size of the effect is uncertain, but even the lower end points to a real increase. A second Chinese study found the same direction: women in the highest third of PFDoA had higher gestational diabetes risk, and related chemicals in the family tracked with higher fasting and after-meal blood sugar. Both studies measured the chemical in serum, not urine.

Liver Scarring in Fatty Liver Disease

In a study of 100 people with fatty liver disease, serum PFDoA levels were higher in those with significant liver scarring than in those without, a difference that reached statistical significance. This is a single, relatively small snapshot study, and again it measured the chemical in serum rather than urine, so it points to a possible link with worse liver disease severity rather than proving one.

Heart Disease and Childhood Asthma

In a large US survey of 10,859 adults, higher total PFAS burden was associated with more prevalent cardiovascular disease, and PFDoA specifically was linked to congestive heart failure and to angina (chest pain from reduced blood flow to the heart). In Taiwanese children, those in the highest quartile of PFDoA had about 80 percent higher odds of asthma (adjusted odds ratio 1.81, 95% CI 1.02 to 3.23).

These are observational associations measured in blood, not proof that the chemical caused the disease, and they sit within a broader pattern that ties overall PFAS exposure to these conditions rather than singling out this one compound. More recent prospective studies and meta-analyses of PFAS and cardiovascular disease have been mixed, with some finding null or even inverse associations, and one 2025 meta-analysis found no overall link between PFAS and childhood asthma onset.

The Findings That Point the Other Way

Not every study shows higher PFDoA lining up with worse health. In one birth cohort, higher maternal PFDoA was associated with slightly greater infant weight-for-length in the first year. In another pregnancy study, higher PFDoA was associated with lower odds of heavy bleeding after delivery (odds ratio 0.42, 95% CI 0.22 to 0.80), roughly 58 percent lower. A birth-outcomes meta-analysis, by contrast, linked PFDoA to shorter birth length and smaller head circumference.

Here is how to hold these together without whiplash. This is an exposure marker, not a tidy 'good number versus bad number' test. Each of these results is a single observational study in a different population, looking at a different endpoint, with different sources of confounding. They do not yet form a consistent dose-response story, and no threshold has been established at which risk clearly turns on. The honest read is that higher exposure raises concern across several outcomes, while the details remain unsettled.

Where Your Exposure Comes From

For most people, this chemical enters through contaminated drinking water and food, with seafood and other animal products among the larger dietary contributors, though PFDoA-specific dietary data are limited and the broader seafood literature centers more on other PFAS. Indoor dust and air play a smaller role.

Certain jobs stand out. PFDoA has been detected in workers at acrylic fiber and chemical plants, and in a fluorochemical manufacturing study, workers carried far more urinary PFAS than nearby residents (a urinary sum around 201 versus about 6 ng/mL, where ng/mL is a unit for very small blood or urine concentrations). Healthcare workers had about 2.5 times the odds of detectable PFDoA compared with other essential workers (adjusted odds ratio 2.50, 95% CI 1.17 to 5.34), a signal researchers attribute to unrecognized workplace sources such as protective equipment and medical supplies.

How Long It Stays In You

There is no direct human clearance estimate for PFDoA in the available research, but its long-chain cousins give a strong hint. Related persistent PFAS have half-lives measured in years: roughly 2.4 to 3.9 years for one common compound, 3.3 to 5.4 years for another, and 5.3 to 15.5 years for a third, with estimates varying widely across study populations and methods. As a long-chain chemical, PFDoA likely clears slowly too, and urine captures only part of how it leaves the body.

The practical takeaway: a single reading is not a snapshot of only the last few days. It reflects chronic background or occupational exposure with some influence from recent input. This slow turnover also shapes how often retesting makes sense.

Why One Reading Is Not Enough

No study has established how much this chemical naturally varies within the same person from test to test, so a single urine value should not drive conclusions on its own. Urine concentration also shifts with how much water you drank beforehand, which adds noise to any one measurement.

The more useful approach is to establish a baseline, then retest to see a trajectory. Because the underlying chemical clears over years, meaningful change is slow, so retesting every few months will mostly show noise. A sensible cadence is a baseline now, then a follow-up 6 to 12 months after a real change in exposure (a new water source, a job change, installing a water filter), and periodically after that. Keep in mind that on the urine sample, changes will be harder to detect for this particular chemical than they would be in blood.

When Results Can Be Misleading

A few factors can distort a single reading or your interpretation of it:

• Recent seafood intake: eating fish shortly before testing can nudge your PFAS level up, because seafood is a genuine dietary source. In one study, higher fish intake tracked with higher blood PFDoA.
• Urine dilution: drinking a lot of water before the test dilutes the sample and can lower the number without changing your true burden. A first-morning sample before eating or drinking reduces this error.
• Age: older adults tend to carry more accumulated PFAS, so age shapes what a 'typical' level looks like.
• Kidney function: because the kidneys handle clearance of these chemicals, changes in kidney function can shift how much appears in urine relative to blood.

What an Unexpected Result Should Prompt

If your urine level is detectable or higher than you expected, the most informative next step is a paired serum PFAS panel, since blood is the better matrix for this long-chain chemical and lets you see the fuller picture. Alongside that, look at your exposure sources: test your drinking water if you use a private well or live near known contamination, and consider whether your job involves PFAS-containing materials.

Combinations matter more than any single value. Detectable PFDoA plus an occupational exposure plus an abnormal metabolic marker is a stronger reason to act than any of those alone. If you are pregnant or planning pregnancy, pairing this with glucose monitoring (such as HbA1c, a measure of average blood sugar, or a glucose tolerance test) is reasonable given the gestational diabetes signal. For persistent or high exposure, an occupational or environmental medicine specialist or a toxicologist is the right person to help you interpret and act on the full set of results.